Sunshine Biopharma Files 8-K on Shareholder Vote Matters
Ticker: SBFMW · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: SBFM
TL;DR
Sunshine Biopharma filed an 8-K on 6/28 for shareholder vote matters.
AI Summary
Sunshine Biopharma, Inc. filed an 8-K on June 28, 2024, reporting on matters submitted to a vote of security holders. The filing indicates a change in the company's reporting status and includes details about its corporate structure and financial reporting.
Why It Matters
This filing is important for investors to understand the corporate governance and any significant decisions made by Sunshine Biopharma's shareholders.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on shareholder votes and corporate information, not indicating immediate financial distress or significant new risks.
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- June 28, 2024 (date) — Date of earliest event reported
- Colorado (jurisdiction) — State of incorporation
- 001-41282 (identifier) — Commission File Number
- 20-5566275 (identifier) — IRS Employer ID No.
- 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale , FL 33301 (address) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 28, 2024.
In which state was Sunshine Biopharma, Inc. incorporated?
Sunshine Biopharma, Inc. was incorporated in Colorado.
What is the Commission File Number for Sunshine Biopharma, Inc.?
The Commission File Number for Sunshine Biopharma, Inc. is 001-41282.
What is the business address of Sunshine Biopharma, Inc. as listed in the filing?
The business address is 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-07-02 16:05:31
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 26KB
- 0001683168-24-004601.txt ( ) — 237KB
- sbfm-20240628.xsd (EX-101.SCH) — 3KB
- sbfm-20240628_def.xml (EX-101.DEF) — 26KB
- sbfm-20240628_lab.xml (EX-101.LAB) — 36KB
- sbfm-20240628_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 28, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the "Company"), approved by written consent an amendment to the Company's articles of incorporation to effect a reverse split of the Company's common stock at a ratio of up to 60-for-1. The consent will be effective 20 days after the definitive information statement relating to such consent is mailed to shareholders. As of June 28, 2024, Dr. Slilaty, who is the Company's chief executive officer, held 84.8% of the total voting power of the Company's stockholders. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 2, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3